FDIQ yields 2.52% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 8
Combined, FDIQ + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FDIQ + JNJ for your $10,000?
The Fund generally will invest at least 90% of its total assets in securities that comprise the New Underlying Index. The Index Provider compiles, maintains and calculates the New Underlying Index, which is designed to track the companies that, in the view of the Index Provider, provide essential services and technologies to the global financial system utilizing research from Bloomberg Intelligence (BI) (an affiliate of the Index Provider) and industry classifications pursuant to the Bloomberg Industry Classification Standard (BICS). To be eligible for inclusion in the New Underlying Index, a security must (i) be part of the Bloomberg developed markets universe (which as of the date of this document, consists of Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hong Kong, Ireland, Israel, Italy, Japan, the Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Switzerland, Sweden, the United Kingdom and the United States), (ii) be classified by the Index Provider pursuant to BICS as a financial information services company or a security & commodity exchanges company, or be classified by BI as a enterprise fintech company within BIs capital markets category, (iii) qualify as a large-, mid-, or small-capitalization company based on metrics developed by the Index Provider, (iv) have minimum free float market capitalization of $500 million, and (v) have a minimum 90-day average daily value traded of $5 million. Each security is weighted based on its modified market capitalization. The maximum weight of each security is generally capped at 4.5% of the New Underlying Index. The New Underlying Index is rebalanced quarterly after the close of trading on the third Friday of January, April, July and October.
Full FDIQ Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.